On August 19, Merck rose 8.75% in regular trading, trading at $145.706/share, with turnover of $526 million.

On the news front, Merck and Moderna jointly announced that their pivotal Phase III clinical trial Interpath-001 achieved its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival. The trial evaluated individualized neoantigen therapy intismeran autogene in combination with Keytruda in patients with completely resected stage IIB-IV melanoma. Results demonstrated statistically significant and clinically meaningful improvements in both endpoints compared with Keytruda alone, with patients receiving the combination therapy showing substantial reductions in risk of disease recurrence or death. Safety data remained consistent with previously reported results, with no new safety signals identified.

Both companies stated they plan to engage with regulatory authorities regarding submission filings for the combination therapy, aiming to advance it into the regulatory review process as quickly as possible. The trial will continue to evaluate other secondary endpoints, including overall survival.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)